Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
VWAGY Volkswagen AG
MLVF Malvern Bancorp Inc
GBCI Glacier Bancorp Inc

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
Day's Change
-0.01 (-0.42%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Affirm Holdings, Inc. (AFRM) Investors with Substantial Losses to Contact the Firm

10:23 am ET April 27, 2022 (PR Newswire) Print

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Affirm Holdings, Inc. ("Affirm") (NASDAQ: AFRM). The action charges Affirm with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Affirm's materially misleading statements to the public, Affirm's investors have suffered significant losses.


Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.


CLICK HERE TO SUBMIT YOUR AFFIRM LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/afrm-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=afrm



CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:James Maro, Esq. at (484) 270-1453 or via email at info@ktmc.com

AFFIRM'S ALLEGED MISCONDUCTAffirm describes itself as a "next generation platform for digital and mobile-first commerce." Through its platform, Affirm offers "buy now, pay later" or "BNPL" services to consumers. Affirm represents itself "a more flexible and transparent alternative to credit cards."

On February 12, 2021, Affirm issued a post-market press release announcing Affirm's fiscal year 2021 second quarter results. The press release quoted Max Levchin, Affirm's Chairman of the Board of Directors and Chief Executive Officer, who stated, in relevant part, that: Affirm's "mission has been to build honest financial products that improve lives"; "[w]e've aligned our success with the success of both sides of the commerce ecosystem, winning when our consumers . . . win"; and "we remain committed to empowering consumers to take control of their finances[.]"

Then, on December 16, 2021, the Consumer Financial Protection Bureau (CFPB) announced that it had launched an inquiry into Affirm's BNPL payment service, along with four other companies offering BNPL. The CFPB indicated that it was concerned about how BNPL leads to accumulating debt, regulatory arbitrage, and data harvesting, and is seeking data on the risks and benefits of the products. In a statement addressing BNPL services, the CFPB Director stated, "[t]he consumer gets the product immediately but gets the debt immediately too." Following this news, Affirm's stock price fell $11.74 per share, or 10.58%, to close at $99.24 per share on December 16, 2021.

Then, at approximately 1:15 p.m. on February 10, 2022, Affirm issued a tweet from its official Twitter account, wherein Affirm disclosed certain metrics from its second quarter 2022 financial results. The Tweet, which was published prior to Affirm's planned release of its financial results, portrayed a highly successful quarter, which included an increase in revenue of 77%. This caused Affirm's share price to spike nearly 10% in intra-day trading. Affirm later deleted the Tweet and released its full second quarter financial results ahead of schedule, which were lackluster, posting a loss of $0.57 per share, compared with analyst expectations of $0.37 per share. Following this news, Affirm's share price plummeted from an intra-day high of $83.57 per share on February 10, 2022, to close at $58.68 per share, or approximately 32%.

WHAT CAN I DO?Affirm investors may, no later than April 29, 2022 seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Affirm investors who have suffered significant losses to contact the firm directly to acquire more information.


WHO CAN BE A LEAD PLAINTIFF?A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.


Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.280 King of Prussia RoadRadnor, PA 19087(484) 270-1453info@ktmc.com


View original content to download multimedia:https://www.prnewswire.com/news-releases/deadline-reminder--kessler-topaz-meltzer--check-llp-reminds-affirm-holdings-inc-afrm-investors-with-substantial-losses-to-contact-the-firm-301533308.html

SOURCE Kessler Topaz Meltzer & Check, LLP


comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.